Table 2.
Baseline demographic and clinical characteristics of patients with MDR-TB in KwaZulu-Natal, South Africa
| Characteristic | Centralised hospital | All community- based sites |
Site 1 | Site 2 | Site 3 | Site 4 | p-value |
|---|---|---|---|---|---|---|---|
| n=813 | n=736 | n=125 | n=148 | n=202 | n=261 | ||
| Female | 413 (50.8) | 390 (52.9) | 68 (54.4) | 88 (59.5) | 98 (48.5) | 136 (52.1) | 0.233 0.230 |
| Median age (years, IQR) | 34 (27-41) | 36 (28-43) | 36 (28-42) | 37 (28-42) | 34 (26-42) | 36 (29-44) | <0.001 0.531 |
| TB characteristics | |||||||
| Previous TB | 778 (95.7) | 411 (55.8) | 87 (69.6) | 81 (54.7) | 136 (67.3) | 107 (41.0) | <0.001 <0.001 |
| Previous MDR-TB | 10 (1.23) | 53 (7.2) | 6 (4.8) | 17 (11.5) | 16 (7.9) | 14 (5.4) | <0.001 0.098 |
| Sputum-smear positive at diagnosis |
491 (60.4) | 557 (75.7) | 75 (60.0) | 121 (81.8) | 152 (75.3) | 209 (80.1) | <0.001 <0.001 |
| Resistant to ≥3 drugs at diagnosis |
467 (57.4) | 410 (55.7) | 74 (59.2) | 91 (61.5) | 101 (50.0) | 144 (55.2) | 0.364 0.149 |
| Initial regimen ≥6 drugs | 717 (88.2) | 591 (80.3) | 115 (92.0) | 131 (88.5) | 91 (45.1) | 254 (97.3) | 0.492 <0.001 |
| HIV characteristics | |||||||
| HIV-infected, n/total tested (%) |
576/788 (73.1) | 528/692 (76.3) | 96/124 (77.4) | 112/144 (77.8) | 123/189 (65.1) | 197/235 (83.8) | 0.450 <0.001 |
| HIV unknown | 25 (3.1) | 44 (6.0) | 1 (0.8) | 4 (2.7) | 13 (6.4) | 26 (10) | 0.051 <0.001 |
| Patients with available CD4 count |
282 | 345 | 82 | 72 | 92 | 99 | |
| Median baseline CD4 count (cells per μL), (IQR) |
185, (106-300) |
193, (88-329) |
158, (71-286) |
230, (136-366) |
139, (64-322) |
227, (96-365) |
0.943 0.010 |
| On ART, n/total HIV-infected (%)* |
454/554 (82.0) | 440/482 (91.3) | 92/94 (97.9) | 103/106 (97.2) | 116/117 (99.2) | 129/165 (78.2) | 0.225 <0.001 |
Data are number (%), unless otherwise indicated
MDR-TB = multidrug-resistant tuberculosis
IQR = interquartile range
HIV = human immunodeficiency virus
ART = antiretroviral therapy
*
On ART at start of MDR-TB therapy or within two weeks of MDR-TB treatment initiation. Denominator excludes HIV+ patients with missing ART information.